MBC Pharma Inc. Awarded a SBIR Phase I Grant to Investigate Novel Compounds Against Osteomyelitis

14:20 EDT 18 Aug 2017 | Colorado BioScience

MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $594,202 Phase I Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to expand their discovery pipeline to include bone-targeted antibiotics for the treatment of osteomyelitis and other bone infections. The work will focus on the synthesis and efficacy testing of novel bone-targeted conjugates of agents with known anti-infective activities.

“MBC’s bone-targeting approach has successfully been applied to cancer induced bone lesions, as was recently demonstrated in a Phase I clinical trial. We are excited to extend this platform to address the very challenging-to-treat problem of bone infection. There is a real need for new therapies for the patients suffering from osteomyelitis; this grant funding will allow us to test newly designed bone-homing conjugates of antibiotics, which have a great potential to repeat success we’ve had with bone-targeted anti-cancer agents,” said Dr. Shawn Zinnen, CEO and the Principal Investigator on the SBIR grant.

“We are excited to be able to evaluate a novel group of promising bone-targeted drugs using our advanced preclinical models”, added Dr. Douglas Thamm, Professor of Oncology, Colorado State University and co-PI. “The SBIR program continues to be a great help to our efforts and we are grateful for the support and recognition of the potential benefit that MBC technology can offer for many types of bone disease,” said Dr. Alexander Karpeisky, President and CSO.

MBC Pharma is a privately held pharmaceutical company developing bone targeted therapeutics for serious diseases and conditions of bone with an oncology and anti-infectives focus.

For information on MBC Pharma please contact Dr. Alexander Karpeisky at 720-859-4041 or Dr. Shawn Zinnen at 720-859-4040

MBC Pharma, Inc.

Original Article: MBC Pharma Inc. Awarded a SBIR Phase I Grant to Investigate Novel Compounds Against Osteomyelitis


More From BioPortfolio on "MBC Pharma Inc. Awarded a SBIR Phase I Grant to Investigate Novel Compounds Against Osteomyelitis"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...